Compare Gilead Sciences, Inc. (GILD) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Live Nation Entertainment, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while Live Nation Entertainment, Inc. trades at $178.65 (market cap $41.53B). The key difference: Gilead Sciences, Inc. is far larger — about 3.9× Live Nation Entertainment, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| GILD | LYV | |
|---|---|---|
Market Cap | $163.51B | $41.53B |
Sector | Health | Industrials |
52-Week High | $155.80 | $186.59 |
52-Week Low | $108.22 | $125.61 |
Enterprise Value | $178.05B | $43.03B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Live Nation Entertainment (LYV) trades at $178.62, down 1.62% on the day, with a bullish technical signal supported by moving averages. The company reported $25.2B in 2025 revenue but faces profitability challenges with a net margin of just 0.33% and negative ROE of -24.68%. Recent earnings misses and a $450M legal charge have pressured results, though strong concert demand and ticket sales growth provide optimism.
Analyst consensus remains strongly bullish with 88.6% buy ratings and a $200.20 price target, representing 12% upside. Key risks include execution on profitability, competitive pressures, and discretionary spending sensitivity. The stock's high P/E of 117.5 reflects growth expectations but demands careful monitoring of margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
